| 88.33 -1.17 (-1.31%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 107.33 | 1-year : | 125.37 |
| Resists | First : | 91.9 | Second : | 107.33 |
| Pivot price | 83.35  |
|||
| Supports | First : | 81.45 | Second : | 75 |
| MAs | MA(5) : | 85.71 |
MA(20) : | 82.61 |
| MA(100) : | 77.88 |
MA(250) : | 62.54 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 69.7 |
D(3) : | 61.3 |
| RSI | RSI(14): 56.4  |
|||
| 52-week | High : | 95.31 | Low : | 34.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APGE ] has closed below upper band by 19.1%. Bollinger Bands are 19.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 91.45 - 91.9 | 91.9 - 92.27 |
| Low: | 86.17 - 86.77 | 86.77 - 87.26 |
| Close: | 87.49 - 88.4 | 88.4 - 89.14 |
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Fri, 12 Jun 2026
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock - Investing.com
Fri, 12 Jun 2026
Apogee Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com
Fri, 12 Jun 2026
Apogee Therapeutics (APGE) CEO sells 20,000 shares in planned trades, keeps over 1.09M - Stock Titan
Fri, 12 Jun 2026
Apogee Therapeutics (NASDAQ: APGE) investors back board, pay and auditor - Stock Titan
Thu, 11 Jun 2026
Apogee Therapeutics (APGE) director receives stock options for 7,657 shares - Stock Titan
Thu, 11 Jun 2026
APGE Stock Price, Quote & Chart - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 131 (%) |
| Shares Short | 9,370 (K) |
| Shares Short P.Month | 9,570 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -235 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -20.4 |
| PEG Ratio | 0 |
| Price to Book value | 5.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -23.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|